EcoDrugPlus

Purinergic Receptor P2x 3

Ensembl ID : ENSPLAG00000006982
Gene Symbol: P2RX3
3 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSPLAG00000014686
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSPLAG00000020282
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSPLAG00000003378
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSPLAG00000016430
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSPLAG00000008467
Gene Symbol: P2RY6
2 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPLAG00000010176
Gene Symbol: RAMP1
2 Cross references
191 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPLAG00000015896
Gene Symbol: RAMP1
1 Cross references
184 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSPLAG00000002068
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSPLAG00000022629
Gene Symbol: LOC106955349
3 Cross references
206 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSPLAG00000023427
Gene Symbol: LOC106956630
3 Cross references
230 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta-Like

Ensembl ID : ENSPLAG00000003721
Gene Symbol: LOC106957153
2 Cross references
5 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).